Eli Lilly and Company
Eli Lilly Appoints Lucas Montarce as New CFO
Summary
On September 9, 2024, Eli Lilly and Company announced the appointment of Lucas Montarce as its new executive vice president and chief financial officer (CFO), effective immediately. Montarce, who joined the company in 2001, has held various finance leadership roles and most recently served as the president and general manager for the Spain, Portugal, and Greece hub. He will receive an annualized base salary of $1,000,000 and is eligible for an annualized target bonus of $1,000,000. There are no arrangements or understandings for his selection, and he has no family relationships with other directors or executive officers.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement